Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1467-1473

  Álvaro, Tomás ^a   Lejeune, Marylène ^a   Salvadó, Ma Teresa ^a   Bosch, Ramón ^a   García, Juan F ^b   Jaén, Joaquín ^a   Banham, Alison H ^e   Roncador, Giovanna ^c   Montalbán, Carlos ^d   Piris, Miguel A ^b  

^a HOSPITAL VERGE DE LA CINTA   (Spain)

^b Molecular Pathology Programme   (Spain)

^c Ctro Nac de Invest Oncologicas   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; T LYMPHOCYTE ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TIA 1 CELL; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR IMMUNITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANZYMES; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POLY(A)-BINDING PROTEINS; PROGNOSIS; PROTEINS; RNA-BINDING PROTEINS; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 20044367117     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1869     Document Type: Article

References (45)

1. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997;89: 1376-82.
2. Poppema S, Potters M, Emmens R, Visser L, van den Berg A. Immune reactions in classical Hodgkin's lymphoma. Semin Hematol 1999;36:253-9.
3. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97.
4. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003;170:6183-9.
5. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-8.
6. + regulatory T cells. Nat Immunol 2003;4:330-6.
7. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
8. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53:73-8.
9. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-10.
10. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-42.
11. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-32.
12. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299: 1057-61.
13. + immunoregulatory cells. J Immunol 2001;167:1137-40.
14. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
15. Shresta S, MacIvor DM, Heusel JW, Russell JH, Ley TJ. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci U S A 1995;92:5679-83.
16. Smyth MJ, Street SE, Trapani JA. Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection. J Immunol 2003;171:515-8.
17. Graubert TA, Ley TJ. How do lymphocytes kill tumor cells? Clin Cancer Res 1996;2:785-9.
18. + T lymphocytes. J Immunol 1990;144:574-82.
19. Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991;67:629-39.
20. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-62.
21. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
22. 1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin El. J Pathol 2003; 199:201-7.
23. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-74.
24. Garcia JF, Camacho FI, Morente M, et al. Hodgkin's and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue-microarrays. Blood 2003;101:681-9.
25. Montalban C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22: 1664-73.
26. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62.
27. Brey EM, Lalani Z, Johnston C, et al. Automated selection of DAB-labeled tissue for immunohistochemical quantification. J Histochem Cytochem 2003;51:575-84.
28. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14.
29. Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10:345-50.
30. Maggio E, van den Berg A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13:52-6.
31. + T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86.
32. Poppema S, Visser L. Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 1994;145:37-41.
33. Newcom SR, Kadin ME, Ansari AA, Diehl V. L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-β active at physiologic pH. J Clin Invest 1988;82:1915-21.
34. + T lymphocytes. Int J Cancer 1995;62:5-10.
35. + regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003;14:85-9.
36. Chrobak P. Control of T cell responses, tolerance and autoimmunity by regulatory T cells: current concepts. Acta Medica 2003;46:131-7.
37. + regulatory T cell subsets. J Leukoc Biol 2003;74:471-8.
38. + regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516-20.
39. + T cells mediating skin inflammation. Blood 2003;102:3295-301.
40. + T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A 2003;100:10878-83.
41. + T cell responses. J Exp Med 2003;198:889-901.
42. + T cell activation. Eur J Immunol 2003;33:3473-83.
43. Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 2001;98:11515-20.
44. Bladergroen BA, Meijer CJ, ten Berge RL, et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002;99:232-7.
45. +, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004;103:2238-47.